A compound and an organic optoelectronic device are provided. The compound has the following chemical formula (I): ##STR00001##
chemical formula (I). In the chemical formula (I), X.sub.1 to X.sub.2 are independently selected from O, S, ##STR00002##
and substituted or unsubstituted methylene, and a substituent is selected from hydrogen, deuterium, C.sub.1 to C.sub.30 alkyl, C.sub.1 to C.sub.30 heteroatom-substituted alkyl, C.sub.6 to C.sub.30 aryl, and C.sub.2 to C.sub.30 heteroaryl. X.sub.3 is selected from O, S, substituted or unsubstituted methylene, substituted or unsubstituted methylene, and substituted or unsubstituted silylene, and a substituent is selected hydrogen, deuterium, C.sub.1 to C.sub.30 alkyl, C.sub.1 to C.sub.30 heteroatom-substituted alkyl, C.sub.6 to C.sub.30 aryl, and C.sub.2 to C.sub.30 heteroaryl. R.sub.1 to R.sub.17 are independently selected from hydrogen, deuterium, C.sub.1 to C.sub.30 alkyl, C.sub.1 to C.sub.30 heteroatom-substituted alkyl, C.sub.6 to C.sub.30 aryl, and C.sub.2 to C.sub.30 heteroaryl.

The invention relates to an organic molecule having precisely two units of formula I linked to one another via a single bond or a bridge Y

##STR00001##

where
Y=a divalent group;
X=at each occurrence identically or differently CN and CF.sub.3;
D=chemical unit having a structure of the formula I-1:

##STR00002##

where
#=attachment point of the unit of formula I-1 to the structure of formula I;
A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z;
Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

Compounds as inhibitors of Bcl-2-associated x-protein (BAX) and pharmaceutical compositions thereof are disclosed. Also disclosed are methods of using these compounds for preserving a tissue or treating a disease or disorder in which it is desirable to inhibit BAX.

Compounds as inhibitors of Bcl-2-associated x-protein (BAX) and pharmaceutical compositions thereof are disclosed. Also disclosed are methods of using these compounds for preserving a tissue or treating a disease or disorder in which it is desirable to inhibit BAX.

The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

A rechargeable lithium-ion cell has a cell capacity and includes a positive electrode having a recharged potential and a negative electrode. The rechargeable lithium-ion cell also includes a charge-carrying electrolyte. The charge-carrying electrolyte includes a charge-carrying medium and a lithium salt. The rechargeable lithium-ion cell also includes a redox shuttle having the following structure. Formula (I)

##STR00001##

A rechargeable lithium-ion cell has a cell capacity and includes a positive electrode having a recharged potential and a negative electrode. The rechargeable lithium-ion cell also includes a charge-carrying electrolyte. The charge-carrying electrolyte includes a charge-carrying medium and a lithium salt. The rechargeable lithium-ion cell also includes a redox shuttle having the following structure. Formula (I)

##STR00001##